CSL的利润在政策转变和结构调整中暴跌81%,引发投资者担忧和股本低落,然而该公司坚持其全年展望,并承诺15亿美元用于美国生产扩张。 CSL's profit plummeted 81% amid policy shifts and restructuring, triggering investor worry and a stock low, yet the company upheld its full-year outlook and pledged $1.5 billion for U.S. production expansion.

澳大利亚最大的生物制药公司CSL(CSL)报告说,前半笔净利润下降81%,降至4.01亿美元,原因是政府政策变化、一次性重组成本和资产损失。 CSL, Australia's largest biopharmaceutical company, reported an 81% drop in first-half net profit to $401 million, citing government policy changes, one-off restructuring costs, and asset impairments. 基本利润从7%跌至19亿美元。 Underlying profit fell 7% to $1.9 billion. 其首席执行官突然退休的公告引起了投资者的担忧,将股份投向八年来的最低点。 The announcement of its CEO's surprise retirement triggered investor concern, sending shares to an eight-year low. 尽管经济下滑,该公司仍维持全年指导,并宣布投资15亿美元,以扩大国内生产。 Despite the downturn, the company maintained its full-year guidance and announced a $1.5 billion U.S. investment to expand domestic production.